Skip to content
★ Sign in to follow
VL

V. Luxco S.a r.l. Versant

Aprea Therapeutics, Inc.
Total declarations
16
Company
1
▲ Purchases (1 ops.)
€4.6M
▼ Sales (0 ops.)
—

Latest filing published 20 May 2020 for Aprea Therapeutics, Inc..

Filing timeline

BuySale
V. Luxco S.a r.l. Versant

Insider track record

Disclosed buys
1
Disclosed sells
0
Signal history

No signal scores available.

Closed purchases

Market purchases
1

Not enough history yet: 0 closed purchases, at least 2 are needed.

Purchases by company

V. Luxco S.a r.l. Versant: trading record in brief

V. Luxco S.a r.l. Versant discloses dealings in Aprea Therapeutics, Inc. to SEC (Form 4). The record holds 16 filings, for trades running from 7 October 2019 to 18 May 2020.

Purchases make up the whole of the open-market record (1 purchase, €4.6M). Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket.

On 20 May 2020 came the latest disclosure, a transaction in Aprea Therapeutics, Inc. The last purchase on record was published on 7 October 2019, which is 2,590 days ago. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. US insiders must file a Form 4 within two business days of a trade. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.

Companies and markets linked to V. Luxco S.a r.l. Versant

Open company profiles for insider transactions, fundamentals and analyst consensus when available.

Declarations16 total

16 of 16 declarations